On July 09, 2025 CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of cancer, reported the close of a $93,390,000 million financing. The proceeds from this round will be used to advance CoRegen’s chemistry, manufacturing, and controls (CMC) development, initiate a Phase 1/2 clinical trial for its steroid receptor coactivator 3 knock-out Regulatory T (Treg) cells (SRC3-KO) program in patients with various solid-tumor types in the first half of 2026 and expand its leadership team with key hires to drive execution and support the company’s growth.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The financing was accomplished under a private placement with a select number of investors. This funding builds upon CoRegen’s prior $28 million raise in early 2024, which supported the acquisition of an exclusive license from Baylor College of Medicine to sponsor the development of its innovative gene regulatory platform.
"We are delighted to have the support of our investors during this pivotal time of growth for the company," said Suneet Varma, CoRegen’s newly appointed Chairman. "This year marks a watershed moment as we build upon the tremendous scientific progress made by Dr. Bert O’Malley and his team at the Baylor College of Medicine. As we prepare to enter the clinic, we are motivated by the belief we have a potentially paradigm-shifting solution in our master gene regulatory platform for patients with some of the most difficult-to-treat solid-tumor cancers, including but not limited to triple negative breast cancer and glioblastoma, for which research to date hasn’t yet moved the needle in a meaningful way in many years. We believe our technology, a type of adoptive cell therapy (ACT), may provide a novel approach for unleashing the healing power of the immune system to eradicate additional forms of cancer."
CoRegen’s platform is based on the groundbreaking work on SRCs (steroid receptor coactivators) in the lab of Bert O’Malley, M.D., Chancellor at the Baylor College of Medicine, who is considered the "Father of Molecular Endocrinology." SRC-3 is overexpressed in most human cancers, and Treg cells’ cancer protection activity is dependent on SRC-3 in this critical immune cell type. Building on this work, CoRegen has carefully engineered cells where SRC-3 is knocked out through application of its proprietary platform, therefore allowing for the targeting of a broad network of immune checkpoint genes for a superior anti-tumor effect. These SRC genes, discovered 30 years ago by Dr. O’Malley, can regulate a wide number of genes in the body, making them an ideal master on-off switch for either stimulating or suppressing gene expression.
(Press release, CoRegen, JUL 9, 2025, View Source [SID1234663767])